Stephen F Kralik1, Todd R Mereniuk2, Laurent Grignon3, Chie-Schin Shih4, Chang Y Ho3, Whitney Finke3, Peter W Coleman2, Gordon A Watson2, Jeffrey C Buchsbaum5. 1. Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana. Electronic address: steve.kralik@gmail.com. 2. Department of Radiation Oncology, Simon Cancer Center, Indiana University, Indianapolis, Indiana. 3. Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana. 4. Department of Pediatrics, Hematology/Oncology Section, Indiana University School of Medicine, Indianapolis, Indiana. 5. Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana.
Abstract
PURPOSE: Proton beam radiation therapy (PBT) has been increasingly used to treat pediatric brain tumors; however, limited information exists regarding radiation-induced cerebral microbleeds (CMBs) among these patients. The purpose of this study was to evaluate the incidence, risk factors, and imaging appearance of CMBs in pediatric patients with brain tumors treated with PBT. MATERIALS AND METHODS: A retrospective study was performed of 100 pediatric patients with primary brain tumors treated with PBT. CMBs were diagnosed by examination of serial magnetic resonance imaging scans, including susceptibility-weighted imaging. Radiation therapy plans were analyzed to determine doses to individual CMBs. Clinical records were used to determine risk factors associated with the development of CMBs in these patients. RESULTS: The mean age at time of PBT was 8.1 years. The median follow-up duration was 57 months. The median time to development of CMBs was 8 months (mean, 11 months; range, 3-28 months). The percentage of patients with CMBs was 43%, 66%, 80%, 81%, 83%, and 81% at 1 year, 2 years, 3 years, 4 years, 5 years, and >5 years from completion of proton radiation therapy. Most of the CMBs (87%) were found in areas of brain exposed to ≥30 Gy. Risk factors included maximum radiation therapy dose (P = .001), percentage and volume of brain exposed to ≥30 Gy (P = .0004, P = .0005), and patient age at time of PBT (P = .0004). Chemotherapy was not a significant risk factor (P = .35). No CMBs required surgical intervention. CONCLUSIONS: CMBs develop in a high percentage of pediatric patients with brain tumors treated with proton radiation therapy within the first few years after treatment. Significant risk factors for development of CMBs include younger age at time of PBT, higher maximum radiation therapy dose, and higher percentage and volume of brain exposed to ≥30 Gy. These findings demonstrate similarities with CMBs that develop in pediatric patients with brain tumor treated with photon radiation therapy.
PURPOSE: Proton beam radiation therapy (PBT) has been increasingly used to treat pediatric brain tumors; however, limited information exists regarding radiation-induced cerebral microbleeds (CMBs) among these patients. The purpose of this study was to evaluate the incidence, risk factors, and imaging appearance of CMBs in pediatric patients with brain tumors treated with PBT. MATERIALS AND METHODS: A retrospective study was performed of 100 pediatric patients with primary brain tumors treated with PBT. CMBs were diagnosed by examination of serial magnetic resonance imaging scans, including susceptibility-weighted imaging. Radiation therapy plans were analyzed to determine doses to individual CMBs. Clinical records were used to determine risk factors associated with the development of CMBs in these patients. RESULTS: The mean age at time of PBT was 8.1 years. The median follow-up duration was 57 months. The median time to development of CMBs was 8 months (mean, 11 months; range, 3-28 months). The percentage of patients with CMBs was 43%, 66%, 80%, 81%, 83%, and 81% at 1 year, 2 years, 3 years, 4 years, 5 years, and >5 years from completion of proton radiation therapy. Most of the CMBs (87%) were found in areas of brain exposed to ≥30 Gy. Risk factors included maximum radiation therapy dose (P = .001), percentage and volume of brain exposed to ≥30 Gy (P = .0004, P = .0005), and patient age at time of PBT (P = .0004). Chemotherapy was not a significant risk factor (P = .35). No CMBs required surgical intervention. CONCLUSIONS:CMBs develop in a high percentage of pediatric patients with brain tumors treated with proton radiation therapy within the first few years after treatment. Significant risk factors for development of CMBs include younger age at time of PBT, higher maximum radiation therapy dose, and higher percentage and volume of brain exposed to ≥30 Gy. These findings demonstrate similarities with CMBs that develop in pediatric patients with brain tumor treated with photon radiation therapy.
Authors: Tiina Maria Remes; Maria Helena Suo-Palosaari; Päivi K T Koskenkorva; Anna K Sutela; Sanna-Maria Toiviainen-Salo; Pekka M Arikoski; Mikko O Arola; Vesa-Pekka Heikkilä; Mika Kapanen; Päivi Maria Lähteenmäki; Tuula R I Lönnqvist; Hannele Niiniviita; Tytti M-L Pokka; Liisa Porra; V Pekka Riikonen; Jan Seppälä; Kirsti H Sirkiä; Antti Vanhanen; Heikki M J Rantala; Arja H Harila-Saari; Marja K Ojaniemi Journal: Neurooncol Pract Date: 2020-02-07
Authors: Ethan B Ludmir; Anita Mahajan; Arnold C Paulino; Jeremy Y Jones; Leena M Ketonen; Jack M Su; David R Grosshans; Mary Frances McAleer; Susan L McGovern; Yasmin A Lassen-Ramshad; Adekunle M Adesina; Robert C Dauser; Jeffrey S Weinberg; Murali M Chintagumpala Journal: Neuro Oncol Date: 2019-05-06 Impact factor: 12.300
Authors: Michael C Jin; Siyu Shi; Adela Wu; Navjot Sandhu; Michael Xiang; Scott G Soltys; Susan Hiniker; Gordon Li; Erqi L Pollom Journal: Neurooncol Pract Date: 2020-06-18